Related Experiment Videos
CD80 gene therapy for lymph node involvement by gastric carcinoma
Kinshi Kosaka1, Masakazu Yashiro, Yoji Sakate
1Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
International Journal of Oncology
|October 20, 2004
Summary
Gene transfer of CD80 (B7-1) into gastric cancer cells using an adenovirus vector enhanced immune recognition. This approach suppressed lymph node metastasis and shows promise for cancer therapy.
Area of Science:
- Immunology
- Oncology
- Gene Therapy
Background:
- CD80 (B7-1) is crucial for T-cell activation and immune responses.
- Gastric cancers often exhibit reduced CD80 expression, impairing immune surveillance.
- Lymph node metastasis is a significant negative prognostic factor in gastric cancer.
Purpose of the Study:
- To investigate the therapeutic potential of CD80 gene transfer in gastric cancer.
- To evaluate the effects of CD80 gene transfection on cancer cell immune interactions and lymph node metastasis.
Main Methods:
- Adenovirus-mediated CD80 gene transfection into human gastric cancer cells (OCUM-2MLN) in vitro.
- Assessment of cancer cell adhesion to peripheral blood mononuclear cells and cytotoxicity.
- In vivo studies involving intratumoral injection of AdCD80 into gastric tumors in a mouse model.
- Histopathological analysis to examine CD80 expression and tumor microenvironment.
Main Results:
- In vitro, CD80 transfection significantly reduced cancer cell adhesion to PBMCs and decreased cytotoxicity.
- Intratumoral AdCD80 injection suppressed in vivo lymph node metastasis of gastric tumors.
- Histopathology confirmed the presence of CD80-positive cells surrounding the tumor post-treatment.
Conclusions:
- Adenovirus-mediated CD80 gene transfer can enhance anti-tumor immunity.
- This gene therapy approach demonstrates potential for suppressing lymph node spread in gastric cancer.
- CD80 gene therapy represents a promising strategy for in vivo cancer treatment.